The effect of cyclosporine initiation time on the outcome of matched allogeneic stem-cell transplantation following fludarabine-based conditioning
Meirav Kedmi
Departments of Bone Marrow Transplantation & Cancer Immunotherapy and Pediatrics, Hadassah, Hebrew University Medical Center, Jerusalem, Israel
Search for more papers by this authorLilane Dray
Departments of Bone Marrow Transplantation & Cancer Immunotherapy and Pediatrics, Hadassah, Hebrew University Medical Center, Jerusalem, Israel
Search for more papers by this authorSigal Grisariu
Departments of Bone Marrow Transplantation & Cancer Immunotherapy and Pediatrics, Hadassah, Hebrew University Medical Center, Jerusalem, Israel
Search for more papers by this authorIgor B. Resnick
Departments of Bone Marrow Transplantation & Cancer Immunotherapy and Pediatrics, Hadassah, Hebrew University Medical Center, Jerusalem, Israel
Search for more papers by this authorPolina Stepensky
Departments of Bone Marrow Transplantation & Cancer Immunotherapy and Pediatrics, Hadassah, Hebrew University Medical Center, Jerusalem, Israel
Search for more papers by this authorMemet Aker
Departments of Bone Marrow Transplantation & Cancer Immunotherapy and Pediatrics, Hadassah, Hebrew University Medical Center, Jerusalem, Israel
Search for more papers by this authorReuven Or
Departments of Bone Marrow Transplantation & Cancer Immunotherapy and Pediatrics, Hadassah, Hebrew University Medical Center, Jerusalem, Israel
Search for more papers by this authorMichael Y. Shapira
Departments of Bone Marrow Transplantation & Cancer Immunotherapy and Pediatrics, Hadassah, Hebrew University Medical Center, Jerusalem, Israel
Search for more papers by this authorMeirav Kedmi
Departments of Bone Marrow Transplantation & Cancer Immunotherapy and Pediatrics, Hadassah, Hebrew University Medical Center, Jerusalem, Israel
Search for more papers by this authorLilane Dray
Departments of Bone Marrow Transplantation & Cancer Immunotherapy and Pediatrics, Hadassah, Hebrew University Medical Center, Jerusalem, Israel
Search for more papers by this authorSigal Grisariu
Departments of Bone Marrow Transplantation & Cancer Immunotherapy and Pediatrics, Hadassah, Hebrew University Medical Center, Jerusalem, Israel
Search for more papers by this authorIgor B. Resnick
Departments of Bone Marrow Transplantation & Cancer Immunotherapy and Pediatrics, Hadassah, Hebrew University Medical Center, Jerusalem, Israel
Search for more papers by this authorPolina Stepensky
Departments of Bone Marrow Transplantation & Cancer Immunotherapy and Pediatrics, Hadassah, Hebrew University Medical Center, Jerusalem, Israel
Search for more papers by this authorMemet Aker
Departments of Bone Marrow Transplantation & Cancer Immunotherapy and Pediatrics, Hadassah, Hebrew University Medical Center, Jerusalem, Israel
Search for more papers by this authorReuven Or
Departments of Bone Marrow Transplantation & Cancer Immunotherapy and Pediatrics, Hadassah, Hebrew University Medical Center, Jerusalem, Israel
Search for more papers by this authorMichael Y. Shapira
Departments of Bone Marrow Transplantation & Cancer Immunotherapy and Pediatrics, Hadassah, Hebrew University Medical Center, Jerusalem, Israel
Search for more papers by this authorConflicts of Interest: We have no conflicts of interest.
Summary
Cyclosporine (CSA) is the most commonly used medication for GVHD prophylaxis. The initiation time varies from day −4 to day 0. Initially, we gave CSA starting on day −1. However, since 2003 we have changed CSA initiation timing policy in most of our protocols to day −4, to achieve stable and controlled pretransplant CSA levels. Here, we assessed if initiation time impact the outcome of allogeneic stem-cell transplantation (allo-SCT). Data of 261 patients who underwent allo-SCT for hematological malignancies from a fully matched donor, treated with CSA as a single agent for GVHD prophylaxis were prospectively collected. Patients were divided according to CSA initiation time and analyzed for outcome. The acute GVHD severity, cGVHD extent, GVHD-associated mortality were significantly lower in the CSA −4 group. There was no difference in the rate and timing of acute or chronic GVHD. Overall survival did not differ between the groups. We conclude that the initiation of CSA at day −4 reduced the severity of aGVHD, extent of cGVHD, and GVHD-associated mortality without impact on overall survival.
References
- 1 Mohty M, Gaugler B. Inflammatory cytokines and dendritic cells in acute graft-versus-host disease after allogeneic stem cell transplantation. Cytokine Growth Factor Rev 2008; 19: 53.
- 2 Prentice HG, Blacklock HA, Janossy G, et al. Depletion of T lymphocytes in donor marrow prevents significant graft-versus-host disease in matched allogeneic leukaemic marrow transplant recipients. Lancet 1984; 1: 472.
- 3 Storb R, Deeg HJ, Whitehead J, et al. Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. N Engl J Med 1986; 314: 729.
- 4 Yee GC, Self SG, McGuire TR, Carlin J, Sanders JE, Deeg HJ. Serum cyclosporine concentration and risk of acute graft-versus-host disease after allogeneic marrow transplantation. N Engl J Med 1988; 319: 65.
- 5 Martin P, Bleyzac N, Souillet G, et al. Clinical and pharmacological risk factors for acute graft-versus-host disease after paediatric bone marrow transplantation from matched-sibling or unrelated donors. Bone Marrow Transplant 2003; 32: 881.
- 6 Martin P, Bleyzac N, Souillet G, et al. Relationship between CsA trough blood concentration and severity of acute graft-versus-host disease after paediatric stem cell transplantation from matched-sibling or unrelated donors. Bone Marrow Transplant 2003; 32: 777.
- 7 Malard F, Szydlo R, Brissot E, et al. Impact of cyclosporine-A concentration on the incidence of severe acute graft-versus-host disease after allogeneic stem cell transplantation. Biol Blood Marrow Transplant 2010; 16: 28.
- 8 Holler E. Risk assessment in haematopoietic stem cell transplantation: GvHD prevention and treatment. Best Pract Res Clin Haematol 2007; 20: 281.
- 9 Lanino E, Rondelli R, Locatelli F, et al. Early (day −7) versus conventional (day −1) inception of cyclosporine-A for graft-versus-host disease prophylaxis after unrelated donor hematopoietic stem cell transplantation in children. Long-term results of an AIEOP prospective, randomized study. Biol Blood Marrow Transplant 2009; 15: 741.
- 10 Glucksberg H, Storb R, Fefer A, et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation 1974; 18: 295.
- 11 Weiden PL, Sullivan KM, Flournoy N, Storb R, Thomas ED. Antileukemic effect of chronic graft-versus-host disease: contribution to improved survival after allogeneic marrow transplantation. N Engl J Med 1981; 304: 1529.
- 12 Pugatsch T, Oppenheim A, Slavin S. Improved single-step PCR assay for sex identification post-allogeneic sex-mismatched BMT. Bone Marrow Transplant 1996; 17: 273.
- 13 Slavin S, Naparstek E, Nagler A, Ackerstein A, Kapelushnik J, Or R. Allogeneic cell therapy for relapsed leukemia after bone marrow transplantation with donor peripheral blood lymphocytes. Exp Hematol 1995; 23: 1553.
- 14 Nakamura Y, Leppert M, O’Connell P, et al. Variable number of tandem repeat (VNTR) markers for human gene mapping. Science 1987; 235: 1616.
- 15 Kanda Y, Hyo R, Yamashita T, et al. Effect of blood cyclosporine concentration on the outcome of hematopoietic stem cell transplantation from an HLA-matched sibling donor. Am J Hematol 2006; 81: 838.
- 16 Gerull S, Arber C, Bucher C, et al. Cyclosporine levels and rate of graft rejection following non-myeloablative conditioning for allogeneic hematopoietic SCT. Bone Marrow Transplant 2011; 46: 740.
- 17 Esa AH, Converse PJ, Hess AD. Cyclosporine inhibits soluble antigen and alloantigen presentation by human monocytes in vitro. Int J Immunopharmacol 1987; 9: 893.
- 18 Holschermann H, Durfeld F, Maus U, et al. Cyclosporine a inhibits tissue factor expression in monocytes/macrophages. Blood 1996; 88: 3837.
- 19 Panickar KS, Jayakumar AR, Norenberg MD. Differential response of neural cells to trauma-induced free radical production in vitro. Neurochem Res 2002; 27: 161.
- 20 Kumar P, Kumar A. Neuroprotective effect of cyclosporine and FK506 against 3-nitropropionic acid induced cognitive dysfunction and glutathione redox in rat: possible role of nitric oxide. Neurosci Res 2009; 63: 302.
- 21 El-Mas MM, Sharabi FM, El-Gowilly SM, El-Din MM. Inhibition of nitric oxide-guanylate cyclase-dependent and -independent signaling contributes to impairment of beta-adrenergic vasorelaxations by cyclosporine. Biochem Pharmacol 2007; 73: 359.
- 22 Tullberg-Reinert H, Hefti AF. Different inhibitory actions of cyclosporine A and cyclosporine A-acetate on lipopolysaccharide-, interleukin 1-, 1,25 dihydroxyvitamin D3- and parathyroid hormone-stimulated calcium and lysosomal enzyme release from mouse calvaria in vitro. Agents Actions 1991; 32: 321.
- 23 Bortin MM, Gale RP, Kay HE, Rimm AA. Bone marrow transplantation for acute myelogenous leukemia. Factors associated with early mortality. JAMA 1983; 249: 1166.
- 24 Lee SJ, Kim HT, Ho VT, et al. Quality of life associated with acute and chronic graft-versus-host disease. Bone Marrow Transplant 2006; 38: 305.
- 25 Syrjala KL, Chapko MK, Vitaliano PP, Cummings C, Sullivan KM. Recovery after allogeneic marrow transplantation: prospective study of predictors of long-term physical and psychosocial functioning. Bone Marrow Transplant 1993; 11: 319.
